In real-world clinical practice in China, for example, six PD-1 inhibitors, including pembrolizumab, nivolumab, sintilimab, tislelizumab, toripalimab, and camrelizumab, are used to varying degrees as first-line treatment for advanced NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.